Skip to main content
. 2018 May 23;51(1):408–412. doi: 10.4143/crt.2018.138

Fig. 2.

Fig. 2.

Acquired epidermal growth factor receptor (EGFR) L718Q mutation. (A) Computed tomography of the chest showed the tumor at baseline before osimertinib treatment (left), at partial response (middle), and during disease progression (right) after treatment with osimertinib. (B) The browser view reveals the mutational status of the tumor at baseline (top) and after osimertinib therapy (bottom).